Co-Diagnostics (NASDAQ:CODX) is a molecular diagnostics company headquartered in Salt Lake City, Utah, known for its proprietary CoPrimer™ technology. Founded in 2016, the company focuses on the design, development and distribution of molecular diagnostic test kits for the detection of infectious diseases, genetic mutations and other health-relevant biomarkers. Its core platform leverages patented cooperative primers, which are engineered to enhance specificity, sensitivity and cost-effectiveness compared to conventional PCR-based assays.
Through its in-house manufacturing and global supply chain partnerships, Co-Diagnostics produces a range of real-time polymerase chain reaction (qPCR) kits, reagents and customized assay development services. During the COVID-19 pandemic, the company rapidly developed and obtained regulatory approvals for several SARS-CoV-2 detection kits, expanding its product portfolio to cover multiple viral targets and multiplexed testing formats. Beyond COVID-19, Co-Diagnostics has pursued assay development across areas such as tuberculosis, Zika virus, HIV, human papillomavirus (HPV) and oncogene mutations, aiming to address diagnostic needs in both clinical laboratories and point-of-care settings.
Co-Diagnostics maintains a global distribution network spanning North America, Latin America, Europe, Africa and parts of the Asia-Pacific region. The company sells its products under direct supply agreements as well as through regional partners, enabling a broad geographic reach. Co-Diagnostics went public in June 2020 and is listed on the Nasdaq Global Market under the ticker symbol CODX. Leadership is anchored by co-founder and Chief Executive Officer Douglas K. Bryant, who oversees research and development, while a management team with expertise in molecular biology, regulatory affairs and commercial operations drives the company’s strategic growth initiatives.
